Trial Outcomes & Findings for A Study Assessing the Effects of an Experimental Dentifrice in Maintaining Tooth Color Following Tooth Bleaching (NCT NCT06150573)
NCT ID: NCT06150573
Last Updated: 2025-07-24
Results Overview
Tooth color of the facial surfaces of the six anterior maxillary teeth was assessed by a single, trained clinical examiner using the VITA Bleachedguide 3D-MASTER. It consisted of a value-ranked ordered scale from 1 (the lightest) to 29 (the darkest). The shade level of each tooth surface was scored visually by the clinical examiner with reference to the Bleachedguide, where lower score indicated improvement.
COMPLETED
NA
160 participants
At Week 24 after tooth bleaching
2025-07-24
Participant Flow
This study was conducted at a single center in the United States.
A total of 178 participants were screened into the study, 160 participants were enrolled and randomized to treatment (79 participants in the test dentifrice group and 81 participants in the reference dentifrice group). A total of 154 randomized participants completed the study.
Participant milestones
| Measure |
Test Dentifrice
Participants dosed the toothbrush provided with a strip of test dentifrice (5 percent \[%\] Potassium nitrate \[KNO3\], 1% alumina, 5% Sodium tripolyphosphate \[STP\] and 1150 parts per million \[ppm\] fluoride as sodium fluoride) and brushed for two timed minutes twice daily (morning and evening) for up to 27 weeks (dentifrice was used for 2 weeks pre peroxide, 1 week during peroxide and 24 weeks post peroxide application). At Week 3, participants performed the first application of peroxide tooth bleaching as per the instructions provided and continued the application daily for up to 7 days.
|
Reference Dentifrice
Participants dosed the toothbrush provided with a strip of reference dentifrice (dentifrice containing 1150 ppm fluoride as sodium fluoride) and brushed for two timed minutes twice daily (morning and evening) for up to 27 weeks (dentifrice was used for 2 weeks pre peroxide, 1 week during peroxide and 24 weeks post peroxide application). At Week 3, participants performed the first application of peroxide tooth bleaching as per the instructions provided and continued the application daily for up to 7 days.
|
|---|---|---|
|
Overall Study
STARTED
|
79
|
81
|
|
Overall Study
COMPLETED
|
75
|
79
|
|
Overall Study
NOT COMPLETED
|
4
|
2
|
Reasons for withdrawal
| Measure |
Test Dentifrice
Participants dosed the toothbrush provided with a strip of test dentifrice (5 percent \[%\] Potassium nitrate \[KNO3\], 1% alumina, 5% Sodium tripolyphosphate \[STP\] and 1150 parts per million \[ppm\] fluoride as sodium fluoride) and brushed for two timed minutes twice daily (morning and evening) for up to 27 weeks (dentifrice was used for 2 weeks pre peroxide, 1 week during peroxide and 24 weeks post peroxide application). At Week 3, participants performed the first application of peroxide tooth bleaching as per the instructions provided and continued the application daily for up to 7 days.
|
Reference Dentifrice
Participants dosed the toothbrush provided with a strip of reference dentifrice (dentifrice containing 1150 ppm fluoride as sodium fluoride) and brushed for two timed minutes twice daily (morning and evening) for up to 27 weeks (dentifrice was used for 2 weeks pre peroxide, 1 week during peroxide and 24 weeks post peroxide application). At Week 3, participants performed the first application of peroxide tooth bleaching as per the instructions provided and continued the application daily for up to 7 days.
|
|---|---|---|
|
Overall Study
Did not meet study criteria
|
1
|
0
|
|
Overall Study
Adverse Event
|
1
|
0
|
|
Overall Study
Lost to Follow-up
|
0
|
1
|
|
Overall Study
Protocol Violation
|
0
|
1
|
|
Overall Study
Withdrawal by Subject
|
2
|
0
|
Baseline Characteristics
A Study Assessing the Effects of an Experimental Dentifrice in Maintaining Tooth Color Following Tooth Bleaching
Baseline characteristics by cohort
| Measure |
Test Dentifrice
n=79 Participants
Participants dosed the toothbrush provided with a strip of test dentifrice (5% KNO3, 1% alumina, 5% STP and 1150 ppm fluoride as sodium fluoride) and brushed for two timed minutes twice daily (morning and evening) for up to 27 weeks (dentifrice was used for 2 weeks pre peroxide, 1 week during peroxide and 24 weeks post peroxide application). At Week 3, participants performed the first application of peroxide tooth bleaching as per the instructions provided and continued the application daily for up to 7 days.
|
Reference Dentifrice
n=81 Participants
Participants dosed the toothbrush provided with a strip of reference dentifrice (dentifrice containing 1150 ppm fluoride as sodium fluoride) and brushed for two timed minutes twice daily (morning and evening) for up to 27 weeks (dentifrice was used for 2 weeks pre peroxide, 1 week during peroxide and 24 weeks post peroxide application). At Week 3, participants performed the first application of peroxide tooth bleaching as per the instructions provided and continued the application daily for up to 7 days.
|
Total
n=160 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
42.0 years
STANDARD_DEVIATION 11.91 • n=5 Participants
|
37.6 years
STANDARD_DEVIATION 13.04 • n=7 Participants
|
39.8 years
STANDARD_DEVIATION 12.65 • n=5 Participants
|
|
Sex: Female, Male
Female
|
47 Participants
n=5 Participants
|
45 Participants
n=7 Participants
|
92 Participants
n=5 Participants
|
|
Sex: Female, Male
Male
|
32 Participants
n=5 Participants
|
36 Participants
n=7 Participants
|
68 Participants
n=5 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
22 Participants
n=5 Participants
|
21 Participants
n=7 Participants
|
43 Participants
n=5 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
57 Participants
n=5 Participants
|
60 Participants
n=7 Participants
|
117 Participants
n=5 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
|
Race/Ethnicity, Customized
African American/African Heritage
|
13 Participants
n=5 Participants
|
13 Participants
n=7 Participants
|
26 Participants
n=5 Participants
|
|
Race/Ethnicity, Customized
Asian - East Asian Heritage
|
1 Participants
n=5 Participants
|
1 Participants
n=7 Participants
|
2 Participants
n=5 Participants
|
|
Race/Ethnicity, Customized
Asian - Japanese Heritage
|
1 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
1 Participants
n=5 Participants
|
|
Race/Ethnicity, Customized
Asian - South East Asian Heritage
|
7 Participants
n=5 Participants
|
5 Participants
n=7 Participants
|
12 Participants
n=5 Participants
|
|
Race/Ethnicity, Customized
Native Hawaiian or Other Pacific Islander
|
4 Participants
n=5 Participants
|
6 Participants
n=7 Participants
|
10 Participants
n=5 Participants
|
|
Race/Ethnicity, Customized
White - Arabic/North African Heritage
|
4 Participants
n=5 Participants
|
3 Participants
n=7 Participants
|
7 Participants
n=5 Participants
|
|
Race/Ethnicity, Customized
White - White/Caucasian/European Heritage
|
42 Participants
n=5 Participants
|
41 Participants
n=7 Participants
|
83 Participants
n=5 Participants
|
|
Race/Ethnicity, Customized
Multiple
|
7 Participants
n=5 Participants
|
12 Participants
n=7 Participants
|
19 Participants
n=5 Participants
|
PRIMARY outcome
Timeframe: At Week 24 after tooth bleachingPopulation: The modified Intent-To-Treat (mITT) population included all randomized participants who completed at least one use of study product and had at least one assessment of tooth color after the bleaching period. Only those participants with data available at the specified time point were analyzed.
Tooth color of the facial surfaces of the six anterior maxillary teeth was assessed by a single, trained clinical examiner using the VITA Bleachedguide 3D-MASTER. It consisted of a value-ranked ordered scale from 1 (the lightest) to 29 (the darkest). The shade level of each tooth surface was scored visually by the clinical examiner with reference to the Bleachedguide, where lower score indicated improvement.
Outcome measures
| Measure |
Test Dentifrice
n=75 Participants
Participants dosed the toothbrush provided with a strip of test dentifrice (5% KNO3, 1% alumina, 5% STP and 1150 ppm fluoride as sodium fluoride) and brushed for two timed minutes twice daily (morning and evening) for up to 27 weeks (dentifrice was used for 2 weeks pre peroxide, 1 week during peroxide and 24 weeks post peroxide application). At Week 3, participants performed the first application of peroxide tooth bleaching as per the instructions provided and continued the application daily for up to 7 days.
|
Reference Dentifrice
n=79 Participants
Participants dosed the toothbrush provided with a strip of reference dentifrice (dentifrice containing 1150 ppm fluoride as sodium fluoride) and brushed for two timed minutes twice daily (morning and evening) for up to 27 weeks (dentifrice was used for 2 weeks pre peroxide, 1 week during peroxide and 24 weeks post peroxide application). At Week 3, participants performed the first application of peroxide tooth bleaching as per the instructions provided and continued the application daily for up to 7 days.
|
|---|---|---|
|
Adjusted Mean VITA Shade Score at 24 Weeks After Tooth Bleaching
|
12.00 score on a scale
Standard Error 0.355
|
12.06 score on a scale
Standard Error 0.348
|
SECONDARY outcome
Timeframe: At Week 12 after tooth bleachingPopulation: The mITT population. Only those participants with data available at the specified time point were analyzed.
Tooth color of the facial surfaces of the six anterior maxillary teeth was assessed by a single, trained clinical examiner using the VITA Bleachedguide 3D-MASTER. It consisted of value-ranked ordered scale from 1 (the lightest) to 29 (the darkest). The shade level of each tooth surface was scored visually by the clinical examiner with reference to the Bleachedguide, where lower score indicated improvement.
Outcome measures
| Measure |
Test Dentifrice
n=72 Participants
Participants dosed the toothbrush provided with a strip of test dentifrice (5% KNO3, 1% alumina, 5% STP and 1150 ppm fluoride as sodium fluoride) and brushed for two timed minutes twice daily (morning and evening) for up to 27 weeks (dentifrice was used for 2 weeks pre peroxide, 1 week during peroxide and 24 weeks post peroxide application). At Week 3, participants performed the first application of peroxide tooth bleaching as per the instructions provided and continued the application daily for up to 7 days.
|
Reference Dentifrice
n=77 Participants
Participants dosed the toothbrush provided with a strip of reference dentifrice (dentifrice containing 1150 ppm fluoride as sodium fluoride) and brushed for two timed minutes twice daily (morning and evening) for up to 27 weeks (dentifrice was used for 2 weeks pre peroxide, 1 week during peroxide and 24 weeks post peroxide application). At Week 3, participants performed the first application of peroxide tooth bleaching as per the instructions provided and continued the application daily for up to 7 days.
|
|---|---|---|
|
Adjusted Mean VITA Shade Score at 12 Weeks After Tooth Bleaching
|
12.08 score on a scale
Standard Error 0.353
|
11.71 score on a scale
Standard Error 0.346
|
SECONDARY outcome
Timeframe: At Week 12 and Week 24 after tooth bleachingPopulation: The mITT population. Only those participants with data available at the specified time points were analyzed.
Extrinsic dental stain was assessed on the facial surfaces of the 6 maxillary anterior teeth using the MLSI. Area (A) and intensity (I) of extrinsic dental stain were scored separately for each tooth on the scale of 0 to 3 and the mean total score was presented, where 0=area with no stain, 1=Stain covering up to one third of area and light intensity stain, 2=Stain covering up to two thirds of area and moderate intensity stain, 3=Stain covering more than two thirds of area and heavy intensity stain. Total MLSI score = Area score multiplied by Intensity score and ranged from 0 to 9, where lower score indicated improvement.
Outcome measures
| Measure |
Test Dentifrice
n=78 Participants
Participants dosed the toothbrush provided with a strip of test dentifrice (5% KNO3, 1% alumina, 5% STP and 1150 ppm fluoride as sodium fluoride) and brushed for two timed minutes twice daily (morning and evening) for up to 27 weeks (dentifrice was used for 2 weeks pre peroxide, 1 week during peroxide and 24 weeks post peroxide application). At Week 3, participants performed the first application of peroxide tooth bleaching as per the instructions provided and continued the application daily for up to 7 days.
|
Reference Dentifrice
n=81 Participants
Participants dosed the toothbrush provided with a strip of reference dentifrice (dentifrice containing 1150 ppm fluoride as sodium fluoride) and brushed for two timed minutes twice daily (morning and evening) for up to 27 weeks (dentifrice was used for 2 weeks pre peroxide, 1 week during peroxide and 24 weeks post peroxide application). At Week 3, participants performed the first application of peroxide tooth bleaching as per the instructions provided and continued the application daily for up to 7 days.
|
|---|---|---|
|
Adjusted Mean Total Modified Lobene Stain Index (MLSI) Score at 12 and 24 Weeks After Tooth Bleaching
Week 12
|
0.69 score on a scale
Standard Error 0.044
|
0.87 score on a scale
Standard Error 0.043
|
|
Adjusted Mean Total Modified Lobene Stain Index (MLSI) Score at 12 and 24 Weeks After Tooth Bleaching
Week 24
|
0.72 score on a scale
Standard Error 0.053
|
1.03 score on a scale
Standard Error 0.052
|
SECONDARY outcome
Timeframe: At Week 12 and Week 24 after tooth bleachingPopulation: The mITT population. Only those participants with data available at the specified time points were analyzed.
Extrinsic dental stain was assessed on the facial surfaces of the 6 maxillary anterior teeth using the MLSI. The facial surface of each assessable tooth was divided into individual sites. The gingival site was defined as a crescent-shaped band, approximately 2 millimeters wide, adjacent to the free margin of the gingiva and extending to the crest of the interdental papillae of the adjacent teeth. The remainder of the tooth surface was called as body site. Area (A) and intensity (I) of extrinsic dental stain were scored separately for each tooth on the scale of 0 to 3 and the mean score was presented, where 0=area with no stain, 1=Stain covering up to one third of area and light intensity stain, 2=Stain covering up to two thirds of area and moderate intensity stain, 3=Stain covering more than two thirds of area and heavy intensity stain. Total MLSI score = Area score multiplied by Intensity score and ranged from 0 to 9, where lower score indicated improvement.
Outcome measures
| Measure |
Test Dentifrice
n=78 Participants
Participants dosed the toothbrush provided with a strip of test dentifrice (5% KNO3, 1% alumina, 5% STP and 1150 ppm fluoride as sodium fluoride) and brushed for two timed minutes twice daily (morning and evening) for up to 27 weeks (dentifrice was used for 2 weeks pre peroxide, 1 week during peroxide and 24 weeks post peroxide application). At Week 3, participants performed the first application of peroxide tooth bleaching as per the instructions provided and continued the application daily for up to 7 days.
|
Reference Dentifrice
n=81 Participants
Participants dosed the toothbrush provided with a strip of reference dentifrice (dentifrice containing 1150 ppm fluoride as sodium fluoride) and brushed for two timed minutes twice daily (morning and evening) for up to 27 weeks (dentifrice was used for 2 weeks pre peroxide, 1 week during peroxide and 24 weeks post peroxide application). At Week 3, participants performed the first application of peroxide tooth bleaching as per the instructions provided and continued the application daily for up to 7 days.
|
|---|---|---|
|
Adjusted Mean MLSI Score at 12 and 24 Weeks After Tooth Bleaching in Gingival Sites, Interproximal Sites and Body Sites
Mean Gingival MLSI, Week 12
|
0.02 score on a scale
Standard Error 0.012
|
0.03 score on a scale
Standard Error 0.011
|
|
Adjusted Mean MLSI Score at 12 and 24 Weeks After Tooth Bleaching in Gingival Sites, Interproximal Sites and Body Sites
Mean Gingival MLSI, Week 24
|
0.01 score on a scale
Standard Error 0.014
|
0.05 score on a scale
Standard Error 0.014
|
|
Adjusted Mean MLSI Score at 12 and 24 Weeks After Tooth Bleaching in Gingival Sites, Interproximal Sites and Body Sites
Mean Body MLSI, Week 12
|
0.00 score on a scale
Standard Error 0.007
|
0.01 score on a scale
Standard Error 0.007
|
|
Adjusted Mean MLSI Score at 12 and 24 Weeks After Tooth Bleaching in Gingival Sites, Interproximal Sites and Body Sites
Mean Interproximal MLSI, Week 12
|
1.37 score on a scale
Standard Error 0.088
|
1.71 score on a scale
Standard Error 0.086
|
|
Adjusted Mean MLSI Score at 12 and 24 Weeks After Tooth Bleaching in Gingival Sites, Interproximal Sites and Body Sites
Mean Interproximal MLSI, Week 24
|
1.44 score on a scale
Standard Error 0.105
|
2.04 score on a scale
Standard Error 0.103
|
|
Adjusted Mean MLSI Score at 12 and 24 Weeks After Tooth Bleaching in Gingival Sites, Interproximal Sites and Body Sites
Mean Body MLSI, Week 24
|
0.00 score on a scale
Standard Error 0.005
|
0.01 score on a scale
Standard Error 0.004
|
SECONDARY outcome
Timeframe: At Week 12 and Week 24 after tooth bleachingPopulation: The mITT population. Only those participants with data available at the specified time points were analyzed.
Extrinsic dental stain was assessed on the facial surfaces of the 6 maxillary anterior teeth using the MLSI. Area (A) of extrinsic dental stain was scored separately for each tooth on the scale of 0 to 3, where 0=area with no stain, 1=Stain covering up to one third of area, 2=Stain covering up to two thirds of area, 3=Stain covering more than two thirds of area. Total score ranged from 0 to 3, where lower score indicated improvement.
Outcome measures
| Measure |
Test Dentifrice
n=78 Participants
Participants dosed the toothbrush provided with a strip of test dentifrice (5% KNO3, 1% alumina, 5% STP and 1150 ppm fluoride as sodium fluoride) and brushed for two timed minutes twice daily (morning and evening) for up to 27 weeks (dentifrice was used for 2 weeks pre peroxide, 1 week during peroxide and 24 weeks post peroxide application). At Week 3, participants performed the first application of peroxide tooth bleaching as per the instructions provided and continued the application daily for up to 7 days.
|
Reference Dentifrice
n=81 Participants
Participants dosed the toothbrush provided with a strip of reference dentifrice (dentifrice containing 1150 ppm fluoride as sodium fluoride) and brushed for two timed minutes twice daily (morning and evening) for up to 27 weeks (dentifrice was used for 2 weeks pre peroxide, 1 week during peroxide and 24 weeks post peroxide application). At Week 3, participants performed the first application of peroxide tooth bleaching as per the instructions provided and continued the application daily for up to 7 days.
|
|---|---|---|
|
Adjusted Mean MLSI (Area) Score at 12 and 24 Weeks After Tooth Bleaching
Week 12
|
0.55 score on a scale
Standard Error 0.025
|
0.69 score on a scale
Standard Error 0.024
|
|
Adjusted Mean MLSI (Area) Score at 12 and 24 Weeks After Tooth Bleaching
Week 24
|
0.57 score on a scale
Standard Error 0.027
|
0.74 score on a scale
Standard Error 0.027
|
SECONDARY outcome
Timeframe: At Week 12 and Week 24 after tooth bleachingPopulation: The mITT population. Only those participants with data available at the specified time points were analyzed.
Extrinsic dental stain was assessed on the facial surfaces of the 6 maxillary anterior teeth using the MLSI. Intensity (I) of extrinsic dental stain was scored separately for each tooth on the scale of 0 to 3, where 0=no stain, 1=light intensity stain, 2=moderate intensity stain, 3=heavy intensity stain. Total score ranged from 0 to 3, where lower score indicated improvement.
Outcome measures
| Measure |
Test Dentifrice
n=78 Participants
Participants dosed the toothbrush provided with a strip of test dentifrice (5% KNO3, 1% alumina, 5% STP and 1150 ppm fluoride as sodium fluoride) and brushed for two timed minutes twice daily (morning and evening) for up to 27 weeks (dentifrice was used for 2 weeks pre peroxide, 1 week during peroxide and 24 weeks post peroxide application). At Week 3, participants performed the first application of peroxide tooth bleaching as per the instructions provided and continued the application daily for up to 7 days.
|
Reference Dentifrice
n=81 Participants
Participants dosed the toothbrush provided with a strip of reference dentifrice (dentifrice containing 1150 ppm fluoride as sodium fluoride) and brushed for two timed minutes twice daily (morning and evening) for up to 27 weeks (dentifrice was used for 2 weeks pre peroxide, 1 week during peroxide and 24 weeks post peroxide application). At Week 3, participants performed the first application of peroxide tooth bleaching as per the instructions provided and continued the application daily for up to 7 days.
|
|---|---|---|
|
Adjusted Mean MLSI (Intensity) Score at 12 and 24 Weeks After Tooth Bleaching
Week 12
|
0.46 score on a scale
Standard Error 0.023
|
0.52 score on a scale
Standard Error 0.023
|
|
Adjusted Mean MLSI (Intensity) Score at 12 and 24 Weeks After Tooth Bleaching
Week 24
|
0.48 score on a scale
Standard Error 0.027
|
0.60 score on a scale
Standard Error 0.026
|
Adverse Events
Test Dentifrice
Reference Dentifrice
Serious adverse events
| Measure |
Test Dentifrice
n=79 participants at risk
Participants dosed the toothbrush provided with a strip of test dentifrice (5% KNO3, 1% alumina, 5% STP and 1150 ppm fluoride as sodium fluoride) and brushed for two timed minutes twice daily (morning and evening) for up to 27 weeks (dentifrice was used for 2 weeks pre peroxide, 1 week during peroxide and 24 weeks post peroxide application). At Week 3, participants performed the first application of peroxide tooth bleaching as per the instructions provided and continued the application daily for up to 7 days.
|
Reference Dentifrice
n=81 participants at risk
Participants dosed the toothbrush provided with a strip of reference dentifrice (dentifrice containing 1150 ppm fluoride as sodium fluoride) and brushed for two timed minutes twice daily (morning and evening) for up to 27 weeks (dentifrice was used for 2 weeks pre peroxide, 1 week during peroxide and 24 weeks post peroxide application). At Week 3, participants performed the first application of peroxide tooth bleaching as per the instructions provided and continued the application daily for up to 7 days.
|
|---|---|---|
|
Respiratory, thoracic and mediastinal disorders
PULMONARY EMBOLISM
|
0.00%
0/79 • From signing of informed consent form until 5 days after the last administration of the study product or the last study procedure (up to approximately 195 days).
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A serious adverse event (SAE) is a particular category of AE where the adverse outcome is serious.
|
1.2%
1/81 • From signing of informed consent form until 5 days after the last administration of the study product or the last study procedure (up to approximately 195 days).
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A serious adverse event (SAE) is a particular category of AE where the adverse outcome is serious.
|
|
Nervous system disorders
TRANSIENT ISCHAEMIC ATTACK
|
1.3%
1/79 • From signing of informed consent form until 5 days after the last administration of the study product or the last study procedure (up to approximately 195 days).
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A serious adverse event (SAE) is a particular category of AE where the adverse outcome is serious.
|
0.00%
0/81 • From signing of informed consent form until 5 days after the last administration of the study product or the last study procedure (up to approximately 195 days).
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A serious adverse event (SAE) is a particular category of AE where the adverse outcome is serious.
|
Other adverse events
| Measure |
Test Dentifrice
n=79 participants at risk
Participants dosed the toothbrush provided with a strip of test dentifrice (5% KNO3, 1% alumina, 5% STP and 1150 ppm fluoride as sodium fluoride) and brushed for two timed minutes twice daily (morning and evening) for up to 27 weeks (dentifrice was used for 2 weeks pre peroxide, 1 week during peroxide and 24 weeks post peroxide application). At Week 3, participants performed the first application of peroxide tooth bleaching as per the instructions provided and continued the application daily for up to 7 days.
|
Reference Dentifrice
n=81 participants at risk
Participants dosed the toothbrush provided with a strip of reference dentifrice (dentifrice containing 1150 ppm fluoride as sodium fluoride) and brushed for two timed minutes twice daily (morning and evening) for up to 27 weeks (dentifrice was used for 2 weeks pre peroxide, 1 week during peroxide and 24 weeks post peroxide application). At Week 3, participants performed the first application of peroxide tooth bleaching as per the instructions provided and continued the application daily for up to 7 days.
|
|---|---|---|
|
Gastrointestinal disorders
GINGIVAL PAIN
|
19.0%
15/79 • From signing of informed consent form until 5 days after the last administration of the study product or the last study procedure (up to approximately 195 days).
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A serious adverse event (SAE) is a particular category of AE where the adverse outcome is serious.
|
25.9%
21/81 • From signing of informed consent form until 5 days after the last administration of the study product or the last study procedure (up to approximately 195 days).
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A serious adverse event (SAE) is a particular category of AE where the adverse outcome is serious.
|
|
Gastrointestinal disorders
HYPERAESTHESIA TEETH
|
11.4%
9/79 • From signing of informed consent form until 5 days after the last administration of the study product or the last study procedure (up to approximately 195 days).
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A serious adverse event (SAE) is a particular category of AE where the adverse outcome is serious.
|
18.5%
15/81 • From signing of informed consent form until 5 days after the last administration of the study product or the last study procedure (up to approximately 195 days).
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A serious adverse event (SAE) is a particular category of AE where the adverse outcome is serious.
|
|
Gastrointestinal disorders
ORAL MUCOSAL EXFOLIATION
|
8.9%
7/79 • From signing of informed consent form until 5 days after the last administration of the study product or the last study procedure (up to approximately 195 days).
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A serious adverse event (SAE) is a particular category of AE where the adverse outcome is serious.
|
2.5%
2/81 • From signing of informed consent form until 5 days after the last administration of the study product or the last study procedure (up to approximately 195 days).
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A serious adverse event (SAE) is a particular category of AE where the adverse outcome is serious.
|
|
Gastrointestinal disorders
ANGULAR CHEILITIS
|
5.1%
4/79 • From signing of informed consent form until 5 days after the last administration of the study product or the last study procedure (up to approximately 195 days).
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A serious adverse event (SAE) is a particular category of AE where the adverse outcome is serious.
|
0.00%
0/81 • From signing of informed consent form until 5 days after the last administration of the study product or the last study procedure (up to approximately 195 days).
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A serious adverse event (SAE) is a particular category of AE where the adverse outcome is serious.
|
|
Gastrointestinal disorders
CHRONIC CHEEK BITING
|
3.8%
3/79 • From signing of informed consent form until 5 days after the last administration of the study product or the last study procedure (up to approximately 195 days).
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A serious adverse event (SAE) is a particular category of AE where the adverse outcome is serious.
|
1.2%
1/81 • From signing of informed consent form until 5 days after the last administration of the study product or the last study procedure (up to approximately 195 days).
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A serious adverse event (SAE) is a particular category of AE where the adverse outcome is serious.
|
|
Gastrointestinal disorders
GINGIVAL DISCOMFORT
|
3.8%
3/79 • From signing of informed consent form until 5 days after the last administration of the study product or the last study procedure (up to approximately 195 days).
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A serious adverse event (SAE) is a particular category of AE where the adverse outcome is serious.
|
0.00%
0/81 • From signing of informed consent form until 5 days after the last administration of the study product or the last study procedure (up to approximately 195 days).
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A serious adverse event (SAE) is a particular category of AE where the adverse outcome is serious.
|
|
Gastrointestinal disorders
LIP DRY
|
0.00%
0/79 • From signing of informed consent form until 5 days after the last administration of the study product or the last study procedure (up to approximately 195 days).
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A serious adverse event (SAE) is a particular category of AE where the adverse outcome is serious.
|
1.2%
1/81 • From signing of informed consent form until 5 days after the last administration of the study product or the last study procedure (up to approximately 195 days).
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A serious adverse event (SAE) is a particular category of AE where the adverse outcome is serious.
|
|
Gastrointestinal disorders
NAUSEA
|
1.3%
1/79 • From signing of informed consent form until 5 days after the last administration of the study product or the last study procedure (up to approximately 195 days).
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A serious adverse event (SAE) is a particular category of AE where the adverse outcome is serious.
|
0.00%
0/81 • From signing of informed consent form until 5 days after the last administration of the study product or the last study procedure (up to approximately 195 days).
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A serious adverse event (SAE) is a particular category of AE where the adverse outcome is serious.
|
|
Gastrointestinal disorders
NONINFECTIVE GINGIVITIS
|
0.00%
0/79 • From signing of informed consent form until 5 days after the last administration of the study product or the last study procedure (up to approximately 195 days).
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A serious adverse event (SAE) is a particular category of AE where the adverse outcome is serious.
|
1.2%
1/81 • From signing of informed consent form until 5 days after the last administration of the study product or the last study procedure (up to approximately 195 days).
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A serious adverse event (SAE) is a particular category of AE where the adverse outcome is serious.
|
|
Gastrointestinal disorders
ORAL DISCOMFORT
|
1.3%
1/79 • From signing of informed consent form until 5 days after the last administration of the study product or the last study procedure (up to approximately 195 days).
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A serious adverse event (SAE) is a particular category of AE where the adverse outcome is serious.
|
0.00%
0/81 • From signing of informed consent form until 5 days after the last administration of the study product or the last study procedure (up to approximately 195 days).
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A serious adverse event (SAE) is a particular category of AE where the adverse outcome is serious.
|
|
Injury, poisoning and procedural complications
TRAUMATIC ULCER
|
19.0%
15/79 • From signing of informed consent form until 5 days after the last administration of the study product or the last study procedure (up to approximately 195 days).
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A serious adverse event (SAE) is a particular category of AE where the adverse outcome is serious.
|
23.5%
19/81 • From signing of informed consent form until 5 days after the last administration of the study product or the last study procedure (up to approximately 195 days).
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A serious adverse event (SAE) is a particular category of AE where the adverse outcome is serious.
|
|
Injury, poisoning and procedural complications
GINGIVAL INJURY
|
0.00%
0/79 • From signing of informed consent form until 5 days after the last administration of the study product or the last study procedure (up to approximately 195 days).
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A serious adverse event (SAE) is a particular category of AE where the adverse outcome is serious.
|
1.2%
1/81 • From signing of informed consent form until 5 days after the last administration of the study product or the last study procedure (up to approximately 195 days).
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A serious adverse event (SAE) is a particular category of AE where the adverse outcome is serious.
|
|
Respiratory, thoracic and mediastinal disorders
OROPHARYNGEAL PAIN
|
1.3%
1/79 • From signing of informed consent form until 5 days after the last administration of the study product or the last study procedure (up to approximately 195 days).
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A serious adverse event (SAE) is a particular category of AE where the adverse outcome is serious.
|
0.00%
0/81 • From signing of informed consent form until 5 days after the last administration of the study product or the last study procedure (up to approximately 195 days).
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A serious adverse event (SAE) is a particular category of AE where the adverse outcome is serious.
|
|
Infections and infestations
SINUSITIS
|
1.3%
1/79 • From signing of informed consent form until 5 days after the last administration of the study product or the last study procedure (up to approximately 195 days).
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A serious adverse event (SAE) is a particular category of AE where the adverse outcome is serious.
|
0.00%
0/81 • From signing of informed consent form until 5 days after the last administration of the study product or the last study procedure (up to approximately 195 days).
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A serious adverse event (SAE) is a particular category of AE where the adverse outcome is serious.
|
|
Vascular disorders
DEEP VEIN THROMBOSIS
|
0.00%
0/79 • From signing of informed consent form until 5 days after the last administration of the study product or the last study procedure (up to approximately 195 days).
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A serious adverse event (SAE) is a particular category of AE where the adverse outcome is serious.
|
1.2%
1/81 • From signing of informed consent form until 5 days after the last administration of the study product or the last study procedure (up to approximately 195 days).
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A serious adverse event (SAE) is a particular category of AE where the adverse outcome is serious.
|
|
Vascular disorders
HYPERTENSION
|
0.00%
0/79 • From signing of informed consent form until 5 days after the last administration of the study product or the last study procedure (up to approximately 195 days).
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A serious adverse event (SAE) is a particular category of AE where the adverse outcome is serious.
|
1.2%
1/81 • From signing of informed consent form until 5 days after the last administration of the study product or the last study procedure (up to approximately 195 days).
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A serious adverse event (SAE) is a particular category of AE where the adverse outcome is serious.
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee HALEON agreements may vary with individual investigators but will not prohibit any investigator from publishing. HALEON supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.
- Publication restrictions are in place
Restriction type: OTHER